• LAST PRICE
    1.7500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.7500/ 8
  • Ask / Lots
    1.7700/ 2
  • Open / Previous Close
    0.0000 / 1.7500
  • Day Range
    ---
  • 52 Week Range
    Low 0.5031
    High 33.2500
  • Volume
    14,786
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeATHX
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesATHX
Athersys Inc
22.6M
-0.2x
---
United StatesAEZS
Aeterna Zentaris Inc
18.6M
-1.8x
---
United StatesPULM
Pulmatrix Inc
14.1M
-0.6x
---
United StatesHGEN
Humanigen Inc
27.1M
-0.2x
---
United StatesIKT
Inhibikase Therapeutics Inc
19.2M
-1.0x
---
United StatesCYCN
Cyclerion Therapeutics Inc
29.8M
-0.6x
---
As of 2023-02-08

Company Information

Athersys, Inc. is a biotechnology company. It is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. It is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.

Contact Information

Headquarters
3201 Carnegie AveCLEVELAND, OH, United States 44115-2634
Phone
216-431-9900
Fax
216-361-9495

Executives

Independent Chairman of the Board
Ismail Kola
Chief Executive Officer, Director
Daniel Camardo
Interim Chief Financial Officer
Kasey Rosado
Chief Operating Officer
Maia Hansen
Director
Joseph Nolan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$22.6M
Revenue (TTM)
$6.0M
Shares Outstanding
12.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.72
EPS
$-8.00
Book Value
$1.69
P/E Ratio
-0.2x
Price/Sales (TTM)
3.8
Price/Cash Flow (TTM)
---
Operating Margin
-1,413.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.